FTC Orders Valeant to Divest Three Drugs Used to Treat Skin Ailments (VRX)

The Federal Trade Commission said it has approved orders requiring Valeant Pharmaceuticals to divest three drugs used to treat different skin ailments, as conditions of acquiring Ortho Dermatologics from Johnson & Johnson, and Dermik Laboratories, from Sanofi. Under the settlements, Valeant will sell the manufacturing and marketing rights to drug products that treat acne and actinic keratosis, a pre-cancerous skin lesion, to Mylan Pharmaceuticals.
Financial News Network